GSK's Bepirovirsen Enters EMA Review As Potential First-In-Class Functional Cure For Chronic Hepatitis B With Statistically Significant Phase III Results

Benzinga Newsdesk www.benzinga.com Positive 69.6%

Neg 0% Neu 0% Pos 69.6%

Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials.
Nearly 3.2 million people in Europe live with chronic hepatitis B (CHB), a leading cause of liver cancer.1

Comments

No comments yet. Be the first!

GSK&#39;s Bepirovirsen Enters EMA Review As Potential First-In-Class Functional Cure For Chronic Hepatitis B With Statistically Significant Phase III Results